Abstract: A method and apparatus for etching material layers with high uniformity of a lateral etch rate across a substrate using a gas mixture that includes a passivation gas. The passivation gas is provided to a peripheral region of the substrate to passivate sidewalls of the structures being etched.

Abstract: A method and system for processing a substrate in a film removal system. The method includes providing the substrate in a substrate chamber of a film removal system, where the substrate has a micro-feature containing a dielectric film on a sidewall of the micro-feature and a photoresist film covering a portion the dielectric film, and performing a first film removal process using supercritical CO2 processing to remove the portion of the dielectric film not covered by the photoresist film. Following the first film removal process, a second film removal process using supercritical CO2 processing can be performed to remove the photoresist film. Alternately, wet processing can be used to perform one of the first film removal process or the second film removal process.

Abstract: A method of processing a for an electronic device, comprising, at least: a nitridation step (a) of supplying nitrogen radicals on the surface of the electronic device substrate, to thereby form a nitride film on the surface thereof; and a hydrogenation step (b) of supplying hydrogen radicals to the surface of the electronic device substrate. By use of this method, it is possible to recover the degradation in the electric property of an insulating film due to a turnaround phenomenon which can occur at the time of nitriding an Si substrate, etc.

Abstract: A method for fabricating a semiconductor integrated circuit device of the invention comprises feeding oxidation species containing a low concentration of water, which is generated from hydrogen and oxygen by the catalytic action, to the main surface of or in the vicinity of a semiconductor wafer, and forming a thin oxide film serving as a gate insulating film of an MOS transistor and having a thickness of 5 nm or below on the main surface of the semiconductor wafer at an oxide film-growing rate sufficient to ensure fidelity in formation of an oxide film and uniformity in thickness of the oxide film.

Abstract: There is provided a multi-layered structure forming method comprising: (A) forming a first insulating material layer containing a first photo-curing material on a substrate; (B) semi-hardening the first insulating material layer by radiating light having a first wavelength to the first insulating material layer; (C) forming a conductive material layer on the semi-hardened first insulating material layer by ejecting droplets of a conductive material to the semi-hardened first insulating material layer from a nozzle of a liquid droplet ejecting apparatus; (D) forming a second insulating material layer containing a second photo-curing material so as to cover the semi-hardened first insulating material layer and the conductive material layer; and (E) forming a first insulating layer, a conductive layer positioned on the first insulating material, and a second insulating layer covering the first insulating layer and the conductive layer by simultaneously heating the first insulating material layer, the conductive

Abstract: This invention includes methods of depositing a silicon dioxide comprising layer in the fabrication of integrated circuitry, and to methods of forming trench isolation in the fabrication of integrated circuitry. In one implementation, a method of depositing a silicon dioxide comprising layer in the fabrication of integrated circuitry includes flowing an aluminum containing organic precursor to a chamber containing a semiconductor substrate effective to deposit an aluminum comprising layer over the substrate. An alkoxysilanol is flowed to the substrate comprising the aluminum comprising layer within the chamber effective to deposit a silicon dioxide comprising layer over the substrate.

Abstract: In a method of forming a metal oxide, an organic metal compound represented by the following chemical formula is introduced into a chamber to chemisorb the organic metal compound onto a substrate, M[L1]x[L2]y where M represents a metal, L1 and L2 respectively represents a first and second ligands. In addition, x and y are independently integers and a value of (x+y) is 3 to 5. An oxygen-containing compound is introduced into the chamber to form the metal oxide. The metal oxide is formed by reacting an oxygen of the oxygen-containing compound with the metal, and separating the ligand from the metal. Thus, the metal oxide having a superior step coverage and a high dielectric constant may be formed using the organic metal compound by an atomic layer deposition process.

Abstract: This invention includes methods of depositing a silicon dioxide comprising layer in the fabrication of integrated circuitry, and to methods of forming trench isolation in the fabrication of integrated circuitry. In one implementation, a method of depositing a silicon dioxide comprising layer in the fabrication of integrated circuitry includes flowing an aluminum containing organic precursor to a chamber containing a semiconductor substrate effective to deposit an aluminum comprising layer over the substrate. An alkoxysilanol is flowed to the substrate comprising the aluminum comprising layer within the chamber effective to deposit a silicon dioxide comprising layer over the substrate.

Abstract: Fibrous nonwoven mats comprising polyetherimid fibers and a binder comprising a resin and an adhesion promoter, and method of making the mat are disclosed. These mats have several uses and are particularly suited as facer mats for fiber reinforced thermoplastic thermoformable materials. When used as a facer, the mat bonds to the thermoformable material and provides a resin rich outer layer and facilitates bonding to a decorative cover.

Abstract: Disclosed is a water disintegratable sheet including bast/leaf fibers and at least one kind of primary fibers. The bast/leaf fibers have a Canadian Standard freeness value of at most 600 milliliter and occupy 2 to 75% by weight of a total fiber weight of the sheet.

Abstract: It is an object of the present invention to provide a clad glass composition for graded-index rod lens for covering, during manufacturing, a preform glass composition lens of a graded-index rod lens that does not include PbO, in which the composition substantially does not include PbO, and expressed in mol % includes SiO2: 45 to 65, Na2O: 3 to 30, K2O: 0 to 10, MgO: 0 to 15, BaO: 0 to 20, where Na2O+K2O: 3 to 35 and MgO+BaO: 0 to 25, and furthermore includes B2O3: 0 to 15, ZnO: 0 to 10, TiO2: 0 to 10, Y2O3: 0 to 7, ZrO2: 0 to 7, Nb2O5: 0 to 7, In2O3: 0 to 7, La2O3: 0 to 7, Ta2O5: 0 to 10, where B2O3+ZnO+TiO2+Y2O3+ZrO2+Nb2O5+In2O3+La2to 20, and a content of at least one of TiO2 and La2O3 is substantially 0 mol %.

Abstract: A method of manufacturing a cordierite porous body of the present invention is a method of manufacturing the cordierite porous body using a cordierite forming material including an Al source, an Si source, and an Mg source and forming cordierite by firing, characterized in that an inorganic micro balloon containing SiO2 and Al2O3 is used as a part or all of the Al source and the Si source, so that a high-open-porosity cordierite porous body having an extremely low possibility of generating defects causing leakage of a fluid, such as cuts can be manufactured.

Abstract: The invention is a catalyst formed by covering each surface of particles in a ceramic support with an alumina thin film and holding an active catalyst component with the surface of the thin film, which is large in the pore size and porosity and small in the pressure loss irrespectively of forming the alumina thin film on the surface and is produced, for example, by immersing the ceramic support in an aluminum-containing metallic compound, preliminarily firing, immersing in hot water, drying, firing and finally holding the active catalyst component on the alumina thin film on the surface of the support.

Abstract: A quantum limit catalyst. The instant quantum limit catalyst is comprised of atomic aggregations whose dimensions correspond to the quantum limit. In the quantum limit, the atomic aggregations acquire structural configurations and electronic interactions not attainable in the macroscopic limit. The structural configurations possible in the quantum limit correspond to atomic aggregations having bond lengths, bond angles, topologies and coordination environments that differ from those found in the macroscopic limit. The electronic interactions possible in the quantum limit originate from wavefunction overlap and tunneling between atoms and lead to modifications in the magnitude and/or spatial distribution of electron density at catalytic sites to provide improved catalytic properties. Representative quantum limit catalysts include quantum scale atomic aggregations of metal atoms. Examples including catalysts derived from Fe, Mg, V and Co are disclosed.

Abstract: The present invention is an improved filtration system, filtering method and unique chemical composition for capturing mercury and other pollutants in flue gases generated by process gas streams. The improved filtration system may take various forms depending on the type of filter system most desired for a particular application; however, the filter system includes at least a filter element or elements and an adsorbent component having a composition suitable for capturing mercury on the downstream side of the filter element.

Abstract: Medium for chromatographic separations. The medium includes a support with a surface on which interwoven polymers are coated to form a polymer surface. The polymers are covalently linked to the support surface. The polymers are each formed from one or more monomer types and at least one monomer type has an amine functional group. The medium also includes an active molecule immobilized on the polymer surface that is selected to separate reagent materials by chemical structure.

Abstract: Disclosed are novel compounds useful for prevention or control of diseases derived from fungi, a process for producing the same, and novel antifungal agents using the novel compounds. The compounds useful for prevention and treatment of diseases derived from fungi according to the present invention include novel compounds represented by formula (I). The compounds represented by formula (I) have potent antifungal activity against diseases derived from fungi, and do not have phytotoxicity to mammals and agricultural and garden plants, from which diseases should be eliminated, and, even when applied to agricultural and garden plants, have high photostability.

Abstract: A water-base fluid for use in drilling wells and other drilling operation includes a shale clay which swells in the presence of water. The fluid preferably includes: an aqueous based continuous phase, and a shale hydration inhibition agent having the formula: H—(OR)x—[—NH—CH2—CH2—CH2—O—CH2—CH2—NH—]—(R?O)y—H wherein R and R? are independently selectable alkylene groups having 2 to 4 carbon atoms, and wherein x and y have independently selected values such that the sum of x and y is at least 1. The shale hydration inhibition agent should be present in sufficient concentration to reduce the swelling of the shale clay. The fluid may be used for formulating drilling fluids such as water-base drilling muds or clear brine drilling fluids. The fluid may also be used in the slurrification and disposal of drill cuttings that contain water swellable clays or shale clays.

Abstract: The cleaning composition for removing resists includes a salt of hydrofluoric acid and a base not containing a metal (A component), a water-soluble organic solvent (B1 component), at least one organic acid or inorganic acid (C component), water (D component), and, optionally, an ammonium salt (E1 component), and having a pH 4-8. Thus, in manufacturing a semiconductor device, such as a copper interconnecting process, efficiency of removing resist residue and other etching residue after etching or ashing is improved, and corrosion resistance of a copper and an insulating film is also improved.

Abstract: A cleansing product containing: (a) a water insoluble substrate; and (b) a surfactant composition impregnated onto the substrate, the composition containing: (i) at least one lathering surfactant; and (ii) at least about 40% by weight, based on the weight of the composition, of water.

Abstract: A fabric treatment composition is provided. The fabric treatment composition includes a fabric treatment agent and a carrier component for containing the fabric treatment agent in a solid form during operation conditions in a dryer. The fabric treatment composition is constructed for transferring the composition to wet fabric as a result of solubilizing the fabric treatment composition by contacting the fabric treatment composition with the wet fabric during a drying operation in a dryer. A method for treating fabric is provided.

Abstract: The present invention relates to a method of treating glial tumors in a subject, which includes providing a glutamate antagonist or a NMDA receptor antagonist and administering the glutamate antagonist or NMDA receptor antagonist to a subject with a glial tumor of the brain or spinal cord under conditions effective to treat the glial tumor.

Abstract: The present invention provides a polypeptide or a pharmacologically acceptable salt thereof comprising one or more, identical or different, amino acid sequences of A-W—H—X1-D-X2-X3-X4-W—W—X5-X6-X7-X8-B (the meaning of each symbol in the formula is defined in the description) and a pharmaceutical composition for treating an angiogenic disease such as a solid tumor comprising said polypeptide. The present invention also relates to a polynucleotide encoding the above-mentioned polypeptide and use of the polynucleotide in gene therapy.

Abstract: The present invention relates to hormone coating layers having desirable hormone delivery characteristics and product lifetime. In one embodiment, the invention is a hormone composition including a substrate having an external surface, and a coating layer disposed on the external surface. The coating layer preferably includes a polymer web, a UV protectant material, and from about 1 wppm to about 100,000 wppm of a hormone dispersed throughout the polymer web. The invention also relates to methods for making hormone coating materials of the present invention. The coating compositions of the present invention preferably are implemented in human and animal food packaging materials in order to safely and efficiently protect the foodstuffs contained therein from insect infestation.

Abstract: Disclosed are novel peptides including antiarrhythmic peptides that have improved stability. Further disclosed are compositions that include such peptides and methods of using the compositions particularly as medicaments.

Abstract: The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.

Abstract: Compounds that promote growth hormone releasing activity are disclosed. These compounds have the formula: A1-A2-X; A1?-X?; or A1?-Y These compounds can be present in a pharmaceutical composition. The compounds can be used with a second compound that acts as an agonist at the growth hormone releasing hormone receptor or which inhibits the effects of somatostatin. These compounds can be used for a variety of uses such as treating hypothalamic pituitary dwarfism, osteoporosis, burns, or promoting wound healing.

Abstract: The present invention relates to peptides and derivatives thereof showing cell attachment, spreading and detachment activity. Particularly, the present invention relates to the peptide NKDIL (SEQ ID NO:2) and EPDIM (SEQ ID NO:3) and derivatives thereof which promote the cell attachment activity through interaction with ?3?1 integrin as a functional cell receptor and include aspartic acid and isoleucine essential for cell attachment and detachment activity. The peptides and derivatives thereof in the present invention can be used for developing a study of cell attachment activity mediated through various extracellular matrix protein containing ?ig-h3, wound healing, tissue regeneration and metastasis inhibition.

Abstract: A method is provided for the preparation of compounds of the formula (R1)(R2)NC(?X)S(O)nR3 or (R1)(R2)NC(?X)OS(O)nR3, wherein R1, R2 and R3, X and n have any of the meanings defined in the specification. A method is also provided for the detection and quantitation of compounds of the formula (R1)(R2)NC(?X)OS(O)nR3. A method to link a therapeutic agent to a compound that is conjugated to glutathione is also provided for the purpose of improving the therapeutic properties of the therapeutic agent. Novel compounds, intermediates, pharmaceutical compositions and methods of use are also provided.

Abstract: A compound represented by the general formula (I) or a salt thereof: wherein represents —CH?CH—, —CH2—CH2— or the like, between R1 and the carbon atom at 4?-position represents a single bond or a double bond, between R2 and the carbon atom at 5-position represents a single bond or a double bond, and for example, 1) when represents —CH?CH— or —CH2—CH2—, and between R1 and the carbon atom at 4?-position represents a double bond, R1 represents ?C(R11)(R12) (wherein R11 represents a lower alkyl group or the like and R12 represents a hydrogen atom or the like) or the like, and R2 represents a hydroxyl group or the like, or R2 may be combined together with the carbon atom at 5-position to form a carbonyl group, and 2) when represents —CH?CH— or —CH2—CH2—, and between R1 and the carbon atom at 4?-position represents a single bond, R1 represents —OCH(R1a)(R1b) (wherein R1a represents a lower alkyl or the like and R1b represents a hydrogen atom or the like) or the like, and R2 re

Abstract: The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a biodegradable microcarrier or noncarrier.

Abstract: A method for delivering an isolated polynucleotide to the interior of a cell in a vertebrate, comprising the interstitial introduction of an isolated polynucleotide into a tissue of the vertebrate where the polynucleotide is taken up by the cells of the tissue and exerts a therapeutic effect on the vertebrate. The method can be used to deliver a therapeutic polypeptide to the cells of the vertebrate, to provide an immune response upon in vivo translation of the polynucleotide, to deliver antisense polynucleotides, to deliver receptors to the cells of the vertebrate, or to provide transitory gene therapy.

Abstract: The intramuscular electroporated injection of a protease-resistant growth hormone-releasing hormone (“GHRH”) cDNA into rat dams at 16 days of gestation resulted in the enhanced long-term growth of the F1 offspring. The offspring were significantly heavier by one week of age and the difference was sustained to 10 weeks of age. Consistent with their augmented growth, plasma IGF-I concentration of the F1 progeny was increased significantly. The pituitary gland of the offspring was significantly heavier, and contained an increased number of somatotropes (cells producing GH) and lactotrophs (prolactin-secreting cells), and is indicative of an alteration in cell lineages. These unique findings demonstrate that enhanced GHRH expression in pregnant dams can result in intergenerational growth promotion, by altering development of the pituitary gland in the offspring.

Abstract: The present invention provides compositions and methods for modulating the secretion of transcriptionally regulated proteins from recombinant cells. More particularly, the present invention provides compositions and methods for accelerating the secretion dynamics of human insulin from recombinant cells using nonsense mediated mRNA decay of the preproinsulin mRNA transcript.

Abstract: The invention relates to genetic approaches to supply nucleotide sequences encoding modified forms of the native forms of apolipoprotein A-I (ApoA-I): mature ApoA-I, preproApoA-I and proApoA-I; including native ApoA-I modified to contain ApoA-I agonists, peptides which mimic the activity of ApoA-I; ApoA-I superagonists, peptides which exceed the activity of native ApoA-I; and modified native ApoA-I having one or more amphipathic helices replaced by the nucleotide sequences of one or more ApoA-I agonists; for the treatment of disorders associated with dyslipoproteinemia, including cardiovascular disease, atherosclerosis, restenosis, hyperlipidemia, and other disorders such as septic shock.

Abstract: The novel glucocorticoid receptor antagonists are 11?-substituted steroid compounds of formula (I): wherein R1 denotes a methyl group, a methoxy group, or an ethoxy group; wherein R2 denotes a tert.-butyl group, a 1-hydroxy-1-methylethyl group, a 1-methoxy-1-methylethyl group, an ethyl isocrotonate group, or a substituted phenyl group. The method of treating an individual suffering from glucocorticoid-mediated hypogonadism, sexual dysfunctions, and/or infertility includes administering a daily dosage consisting of an effective amount of one of these 11?-substituted steroid compounds.

Abstract: Anlogs of ningalin B lacking inherent cytotoxic activity may be employed to reverse multi-drug resistant (MDR) phenotype and to resensitize transformed cells, including a human colon cancer cell line (HCT116/VM46), with respect to a variety of cytotoxic agents, e.g., vinblastine and doxorubicin. In many instances, resensitization is achieved at lower doses than the prototypical agent verapamil. Total synthesis of ningalin B and its analogs was achieved using a concise, efficient approach based on a heterocyclic azadiene Diels-Alder strategy (1,2,4,5-tetrazine?1,2-diazine?pyrrole) ideally suited for construction of the densely functionalized pyrrole core found in the natural product is detailed.

Abstract: The invention concerns novel benzodiazepine derivatives and their uses in the field of therapeutics particularly for treating pathologies involving the activity of a cyclic nucleotide phosphodiesterase. It also concerns methods for preparing them and novel synthesis intermediates.

Abstract: Compounds of formula (I): wherein: R1 represents hydroxy or RCO—O—, R2 represents hydrogen, halogen, hydroxy or R?CO—O, R, R?, which may be identical or different, represent linear or branched (C1-C6)alkyl optionally substituted by aryl, linear or branched (C2-C6)alkenyl optionally substituted by aryl, linear or branched (C1-C6)perhaloalkyl, (C3-C7)cycloalkyl, adamantyl, aryl or heteroaryl, R3 represents hydrogen, linear or branched (C1-C6)alkyl or (C3-C7)cycloalkyl, A represents CR4R5 or NR4, R4 represents hydrogen or linear or branched (C1-C6)alkyl, their isomers and also their addition salts with a pharmaceutically acceptable acid or base. Medicaments.

Abstract: The present invention is directed to water-soluble derivatives of 2,6-diisopropylphenol (Propofol). The compounds act as prodrugs of 2,6-diisopropylphenol and metabolize rapidly to Propofol thereby providing an alternative to the water-insoluble 2,6-diisopropylphenol. Pharmaceutical compositions comprising these compounds, methods of induction and maintenance of anesthesia or sedation as well as methods of treating neurodegenerative diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

Abstract: Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to C-25 carbamate derivatives of rifamycin having another functional group or pharmacophore covalently attached to this position through a carbamate linkage. The resulting compounds exert their antimicrobial activity through a dual-function mechanism and therefore exhibit reduced frequency of resistance.

Abstract: This invention provides compounds of formula I: wherein a, b, c, e, m, n, Ar1, R1, R2, R3, R4a, R4b, R5 and R6 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

Abstract: The present application describes 1,1-disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, ?-aminoacids, ?-aminoacids and derivatives thereof of Formula I: P-M-M1I or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein M is a linear core. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Abstract: Compounds and compositions of azacytosine analogs and derivatives are provided. In one aspect of the invention, analogs or derivatives of decitabine and azacitidine are provided with modification at the 4- and 6-position of the triazine ring, at the 1?–6? position of the ribose ring, or combinations thereof. Methods of synthesizing and manufacturing these analogs and derivatives are also provided. These compounds can be formulated into pharmaceutical compositions that can be used for treating any disease that is sensitive to the treatment with decitabine or azacitidine, such as hematological disorders and cancer.

Abstract: The present invention relates to compounds of the Formulae (I)-(IV), wherein R1-R6, R11-R13, X and Y are defined herein, and their pharmaceutically acceptable salts.

Abstract: The present invention relates to compounds of Formula I, or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The compounds of the inventions are CRF1 receptor antagonists. Compounds of the invention are useful for treating, in a warm-blooded animal, particularly a mammal, and more particularly a human, various disorders that are associated with CRF or CRF1 receptors, or disorders the treatment of which can be effected or facilitated by antagonizing CRF1 receptors.

Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.

Abstract: A method of treating or preventing chronic organ transplant rejection comprising administering a compound of the formula wherein R1, R2 and R3 are as defined above.

Abstract: A new class of diketo acids constructed on nucleobase scaffolds, designed as inhibitors of HIV replication through inhibition of HIV integrase, is described. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS and ARC, either as the compounds, or as pharmaceutically acceptable salts, with pharmaceutically acceptable carriers, used alone or in combination with antivirals, immunomodulators, antibiotics, vaccines, and other therapeutic agents. Methods of treating AIDS and ARC and methods of treating or preventing infection by HIV are also described.

Abstract: Disclosed is a pharmaceutical composition for preventing and treating addiction to morphine or preventing and inhibiting the development of tolerance to the analgesic effects of morphine, containing berberine as an effective ingredient, wherein the berberine has an inhibitory effect versus psychological dependence on abused drugs such as morphine and the increase of spontaneous locomotor activity upon administration of the drugs, The pharmaceutical composition and a Coptis japonica plant extract of the present invention, which contain berberine, are highly effective in inhibiting the aforementioned symptoms of morphine addiction, and are thus useful for prevention and treatment of addiction to abused drugs such as morphine.